Neumora Therapeutics Reports Q1 Cash, Cash Equivalents And Marketable Securities Of $423M, Which Is Expected To Support Operations Into 2026
Neumora Therapeutics Reports Q1 Cash, Cash Equivalents And Marketable Securities Of $423M, Which Is Expected To Support Operations Into 2026
Neumora Therapeutics報告稱，第一季度現金、現金等價物和有價證券爲4.23億美元，預計將爲2026年的運營提供支持
Neumora Therapeutics Reports Q1 Cash, Cash Equivalents And Marketable Securities Of $423M, Which Is Expected To Support Operations Into 2026
Neumora Therapeutics報告稱，第一季度現金、現金等價物和有價證券爲4.23億美元，預計將爲2026年的運營提供支持
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。